potassium voltage-gated channel subfamily A member 10Genealiases: Kcn1 · Kv1.8
Q-omics provides the consensus-scored KCNA10 profile across patient tissues and cancer cell-line models. KCNA10 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, KCNA10 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, KCNA10 RNA expression shows 6,652 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight CESC, LUSC, and ESCA as cancer lineages where KCNA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNA10 survival associations across molecular data types. KCNA10 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNA10 RNA expression–survival associations across cancer types. High KCNA10 expression shows unfavorable associations in CESC, UVM, BLCA, MESO and TGCT, but favorable associations in SCLC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for KCNA10 RNA expression.
This table summarizes KCNA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNA10 shows lower tumor expression in LUSC and LUAD and higher tumor expression in COAD, HNSC and STAD. The LUSC box plot shows higher KCNA10 RNA expression in normal versus tumor tissue (log2 FC = −0.329, t-test p < 0.001).
This table shows molecular features associated with KCNA10 in patient tissues and cancer cell lines. In patient samples, KCNA10 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
